Physician profile
Karin Clary
NPI 1053307397
$11,541.21
in general payments reported to CMS, 2019-2025
41 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,010 · 2022: $1,889 · 2023: $2,023 · 2024: $2,690 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,472 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,472.28 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,129.02 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,759.12 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $1,120.26 | 2021 | |
| Vanda Pharmaceuticals INC. | $577.89 | 2022-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $502.78 | 2023-2025 | |
| Lundbeck LLC | $486.52 | 2021-2025 | Vyepti, Rexulti |
| Merck Sharp & Dohme LLC | $312.95 | 2021-2023 | Belsomra |
| Eisai INC. | $303.83 | 2021 | |
| Neurocrine Biosciences, INC. | $283.44 | 2021-2024 | Ingrezza |
| Grt US Holding, INC. | $250.57 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $237.08 | 2022-2025 | Belbuca, Xtampza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $223.09 | 2021-2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $218.09 | 2023-2024 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $195.80 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Clary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.